3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-07), VivoSim Labs's 3-1 Month Momentum % is N/A%.
The industry rank for VivoSim Labs's 3-1 Month Momentum % or its related term are showing as below:
FRA:4OR's 3-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -8.46 * Ranked among companies with meaningful 3-1 Month Momentum % only.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
VivoSim Labs 3-1 Month Momentum % Related Terms
FRA:4OR vs SLXN, CDT, CLDI: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, VivoSim Labs's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VivoSim Labs 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VivoSim Labs's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where VivoSim Labs's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VivoSim Labs (FRA:4OR) has a 3-1 Month Momentum % of N/A% as of Jul. 07, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on VivoSim Labs and its competitors. According to the industry distribution chart, VivoSim Labs ranks #1162 out of 1375 companies in the Biotechnology industry, placing it in the top 84.5%.
Is VivoSim Labs' 3-1 Month Momentum % too high?
VivoSim Labs' current 3-1 Month Momentum % is N/A%. Based on the distribution chart, VivoSim Labs ranks #1162 out of 1375 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, VivoSim Labs has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' 3-1 Month Momentum % compare to SLXN and CDT?
According to the Biotechnology industry distribution chart, VivoSim Labs ranks #1162 out of 1375 companies for 3-1 Month Momentum %. This places VivoSim Labs in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on VivoSim Labs and its competitors. VivoSim Labs's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current 3-1 Month Momentum % of N/A%. The stock's GF Value™ is €9.41, compared to a current price of €3.49 — trading 62.9% below its estimated fair value. The current 3-1 Month Momentum % is N/A%. VivoSim Labs' overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current 3-1 Month Momentum % is N/A% as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VivoSim Labs (FRA:4OR) Overvalued in 2026?
Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued.
The current stock price of €3.49 is trading 62.9% below its estimated GF Value™ of €9.41.
Key valuation signals for FRA:4OR:
3-1 Month Momentum %: N/A%
GF Value™: €9.41 vs. price of €3.49 (62.9% below fair value)
No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
38GF Score
Get the complete analysis for FRA:4OR
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4OR has been successfully added to your 